In conclusion, m6A RNA methylation regulators KIAA1429, METTL16, METTL3, IGF2BP2, and YTHDF1, as well as their targets may play a critical role in the occurrence of glioma, which may be beneficial to therapeutic customization and clinical decision-making. This evidence concerns the gene METTL16 and glioma.